JPRN-jRCT2080223582已完成1 期
A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination with Nivolumab (BMS-936558) in Advanced Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Performance status 0-1
- •Adequate organ function
- •Cohort M1, 2 and C1: Measurable disease
- •Cohort M1, M2 and C1: Subjects must have histologic or cytologic confirmation of an advanced (metastatic and/or unresectable) malignant solid tumor
- •Cohort C2: Documented refractory or relapsed multiple myeloma
- •Subjects must be refractory to or have relapsed after standard therapies, or have no known effective treatment
排除标准
- •Cohort M1, M2, and C1: Untreated or active central nervous system (CNS) or leptomeningeal metastases
- •Cohort M1, M2, and C1: Subjects with hepatocellular carcinoma (HCC)
- •Cohort C2: Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.EUCTR2018-000339-28-GBBristol-Myers Squibb International Corporation200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 20.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-DKBristol-Myers Squibb International Corporation200
已完成
2 期
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerJPRN-jRCT2080224088Bristol-Myers Squibb K.K.160
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-DEBristol-Myers Squibb International Corporation200